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Abstract
Understanding the impact of multiple genetic variants and their interactions on the disease penetrance of familial multiple
prostate cancer is very relevant to the overall understanding of carcinogenesis. We assessed the joint effect of two loci on
rs4242382 at 8q24 and rs10486567 at 7p15.2 to this end. We analyzed the data from a Finnish family-based genetic study,
which was composed of 947 men including 228 cases in 75 families, to evaluate the respective effects of the two loci on the
disease penetrance; in particular, the occurrence and number of prostate cancer cases within a family were utilized to
evaluate the interactions between the two loci under the additive and multiplicative Poisson regression models. The risk
alleles A at rs4242382 (OR= 1.14, 95% CI 1.08–1.19, P,0.0001) and a risk allele A at rs10486567 (OR= 1.06, 96%CI 1.01–1.11,
P = 0.0208) were found to be associated with an increased risk of familial PrCa, especially with four or more cases within a
family. A multiplicative model fitted the joint effect better than an additive model (likelihood ratio test X2 = 13.89,
P,0.0001). The influence of the risk allele A at rs10486567 was higher in the presence of the risk allele A at rs4242382
(OR= 1.09 (1.01–1.18) vs. 1.01 (0.95–1.07)). Similar findings were observed in non-aggressive PrCa, but not in aggressive
PrCa. We demonstrated that two loci (rs4242382 and rs10486567) are highly associated with familial multiple PrCa, and the
gene-gene interaction or statistical epistasis was consistent with the Fisher’s multiplicative model. These loci’s association
and epistasis were observed for non-aggressive but not for aggressive tumors. The proposed statistical model can be
further developed to accommodate multi-loci interactions to provide further insights into epistasis.
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Introduction
Genetic predisposition and familial aggregation of prostate
cancer (PrCa) have been demonstrated in numerous studies; a twin
study showed a very high heritability score [1]. Men with one
affected first-degree relative have a two-fold increased risk of PrCa
and even higher risk for an early onset of PrCa compared to those
without such a relative [2,3]. The recent genome-wide association
studies have identified multiple genetic variants in over 40 loci that
are significantly associated with a risk of prostate cancer [4].
Originally, these variants were mainly found in altogether five
chromosomal regions; three independent regions of 8q24, in one
region of 17q12, and one region of 17q24.3[5–9]. However, it has
been reported that a family history is predictive for the risk of
prostate cancer independently of the effect of SNPs in the risk
associated chromosomal regions [1]. In addition to the regions on
chromosomes 8 and 17, a specific SNP in the JAZF1 gene at
7p15.2 has been repeatedly associated with PrCa risk [10–13].
Besides overall risk, of particular interested are its reported
associations with early onset, and aggressive disease, as well as
with biochemical recurrence, suggesting prognostic importance
[14–16].
The SNP known as rs10486567 is located within the intron 2 of
the JAZF1, which encodes a transcriptional repressor of NR2C2, a
nuclear orphan receptor that is highly expressed also in prostate
cancer [13].
Because a number of SNPs are involved in familial risk for
prostate cancer, but their independent main effects explain only a
fraction of the observed heritability, gene-gene interaction
between loci (departure from independence of effects, which is
known as epistasis in genetics and effect modification in
epidemiology) provides a potential improvement in understanding
the hereditary component of prostate cancer [17]. Of the
identified SNPs, we selected two SNPs, a common and consistent
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risk SNP rs4242382 within 8q24 on chromosome 8, and the SNP
rs10486567 within JAFZ1 on chromosome 7 with consistent
associations in various populations and also with different disease
outcomes.
We aimed to evaluate the impact of two loci on rs4242382 and
rs10486567 on the prostate cancer risk within a family. We also
evaluated interactions between the two loci in additive and
multiplicative models. Separate analyses were also conducted for
aggressive and non-aggressive PrCa.
Materials and Methods
Data Sources and study design
The data used for the following analysis are from a population-
based cohort that consisted of patients diagnosed with prostate
cancer in the Pirkanmaa Hospital District and control subjects
selected from the anonymous male blood donors obtained from
the Finnish Red Cross. The study design and the DNA sample
collection have been described in previous studies [18,19]. The
data used for the familial aggregation analysis of PrCa were
derived from a Finnish family study that enrolled 947 subjects
from 76 families with 2–6 family members (Figure 1). We used a
family-based study design by dividing these 947 subjects into 719
unaffected relatives and 228 cases with PrCa. The oldest
unaffected cases were selected for controls from each family.
The mean ages were 61.5 and 65.0 for unaffected relatives and
cases, respectively. Among the 228 patients with prostate cancer,
25% (N=57) were clinically advanced and had Gleason Score$7;
they were classified as aggressive cancers. Through these index
cases, the total of 228 prostate cancer cases among family
members were found to have an outcome following a Poisson
regression model with the genotypes for the two loci, rs4242382 at
8q24 and rs 10486567 at 7p, defined as the independent variables.
Genotype
Two loci, rs4242382 at 8q24 and rs 10486567 at 7p15.2, with
genotypes AA, GA, and GG, were selected for the analysis for the
reasons outlined above. The risk allele A of rs4242382 at 8q24 has
been previously reported to be associated with an aggressive PrCa
[2,8,19–24]. The risk allele G of rs 10486567 at 7p15.2 on the
intron 2 of the JAZF zinc finger1 gene (JAZF1) is commonly
observed in the Europeans [9].
Statistical Analysis
The frequencies of the two SNPs were expressed as percentages.
The frequencies of the genotype AA or GA versus GG are listed by
the number of affected men for the two loci. By taking the number
of PrCa cases among the family members of a proband as the
outcome, we used a multi-variable Poisson regression model to
evaluate the effect of the genotypes AA/GA versus GG for the two
SNPs on the number of PrCa cases in the family. In addition, we
evaluated the gene interactions between the two SNPs under the
two models of statistical epistasis, the additive model and
multiplicative model proposed by Fisher. We used the likelihood
ratio test with Akaike Information Criterion (AIC) measures to
assess whether an additive or a multiplicative model fitted the data
better when it included the two loci vs. only one locus.
Results
Figure 1 shows the families of 947 study subjects, where 719 of
them were healthy and 228 diagnosed with PrCa. They included
30 families with two members with PrCa, 26 families with three,
12 families with four, six families with five, and two families with
six family members diagnosed with PrCa.
The allele frequencies were calculated as 6.4% of AA (n= 61),
31.8% of GA (n= 301), and 61.8% of GG (n= 585) for rs4242382;
6.5% of AA (n= 61), 36.9% of GA (n= 348), and 57.6% of GG
(n= 534) for rs10486567.
Figure 1. Family members with PrCa among 76 Finnish families.
doi:10.1371/journal.pone.0089508.g001
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Table 1. Number of total prostate cancer cases and aggressive prostate cancer cases among the family members stratified by the
alleles for rs4242382 & rs10486567 loci.
SNP-rs4242382 SNP-rs10486567
No. of PrCa cases among
family members GG AA or GA GG AA or GA
All PrCa N % N % N % N %
2 198 65.8 103 34.2 174 57.8 127 42.2
3 228 71.7 90 28.3 193 61.1 123 38.9
4 79 49.7 80 50.3 82 51.9 76 48.1
5+ 80 47.3 89 52.7 85 50.6 83 49.4
P,0.0001 P = 0.0383
Aggressive PrCa
0 265 60.5 173 39.5 257 58.9 179 41.1
1 209 69.0 94 31.0 163 54.0 139 46.0
2 97 53.6 84 46.4 99 55.0 81 45.0
3 14 56.0 11 44.0 15 60.0 10 40.0
P = 0.006 P = 0.546
Total 585 362 534 409
doi:10.1371/journal.pone.0089508.t001
Table 2. The additive model of an association between the two SNPs and the risk of prostate cancer.
One Loci Two Loci
Additive Model
Cancer Type SNPs Coefficient OR (95%CI) p-Value Coefficient aOR (95%CI) p-Value
Prostate Cancer
Intercept 1.1878 1.1707
rs4242382 (AA or GA vs GG) 0.1271 1.1355 ,0.0001 0.1245 1.1326 ,0.0001
(1.0840–1.1895) (1.0808–1.1867)
Intercept 1.2053
rs10486567 (AA or GA vs GG) 0.0550 1.0560 0.0208 0.0424 1.0433 0.0727
(1.0084–1.1071) (0.9961–1.0927)
Non-aggressive
Prostate Cancer
Intercept 1.0608 1.0469
rs4242382 (AA or GA vs GG) 0.1462 1.1575 ,0.0001 0.1453 1.1564 ,0.0001
(1.0776–1.2433) (1.0759–1.2429)
Intercept 1.0800
rs10486567 (AA or GA vs GG) 0.0484 1.0496 0.1858 0.0336 1.0342 0.3562
(0.9770–1.2758) (0.9629–1.1109)
Aggressive
Prostate Cancer
Intercept 20.5249 20.5462
rs4242382 (AA or GA vs GG) 0.0646 1.0667 0.4101 0.0579 1.0596 0.4634
(0.9147–1.2439) (0.9076–1.2371)
Intercept 1.0800
rs10486567 (AA or GA vs GG) 0.0591 1.0609 0.4446 0.0533 1.0548 04927
(0.9117–1.2345) (0.9057–1.2284)
doi:10.1371/journal.pone.0089508.t002
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The frequency of the risk allele A (AA or GA) at rs4242382
increased from 34.2% for families with two PrCa cases up to 53%
for family families with at least five affected members (Table 1).
Similarly, the frequency of the risk allele A at rs10486567
increased from 42.2% for families with two affected members to
49.4% for those with five or more cases. An equally strong relation
was not found for the risk allele frequencies and the number of
aggressive PrCa cases.
In the Poisson regression analysis considering age as a
confounding factor, the risk allele A at rs4242382 was associated
with an increased risk of familial multiple PrCa cases (aOR=1.19,
95% CI 1.08–1.19, P,0.0001, Table 2). In addition, the risk allele
A at rs10486567 showed a significant but slightly weaker effect
(aOR=1.06, 95% CI 1.01–1.11, P= 0.0208).
When the two loci were considered simultaneously in an
additive model, the regression coefficients were slightly decreased
from aOR=1.14 (1.08–1.19) to aOR=1.13 (1.08–1.19) for the
risk allele A at rs4242382, as well as from aOR=1.06 (1.01–1.11)
to aOR=1.04(1.00–1.09) for the risk allele A at rs10486567.
Adding either risk allele improved the fit of the model at a
statistically significant level compared with a single locus model
(risk allele A at rs4242382 resulted in X2(1) = 183.0093, P,0.0001,
and the A at rs10486567 with X2(1) = 16.89, P,0.0001, Table 1),
which suggests that the effects of the two risk alleles were
independent in the context of the additive model. Comparable
results were observed for non-aggressive PrCa, albeit the risk allele
A at rs4242382 was more influential than the risk allele A at
rs10486567 with the latter being non-significant (P = 0.74). For the
aggressive PrCa, no significant improvement was found to the
single locus model when the two-loci model were used (P-values
0.46 and 0.49).
The multiplicative model with an interaction term for the two
SNPs fitted the data significantly better than the corresponding
additive or multiplicative models (P = 0.0002, Table 3;
AIC= 7713.23, see Table S1 in File S1). A significant improve-
ment was also observed for the data from non-aggressive PrCa, but
not from the aggressive PrCa. The effect of the risk allele A at
rs4242382 was modified by the risk allele A at rs10486567, as
shown in Table 3 along with the results of each locus stratification
by the other risk allele A for PrCa and non-aggressive PrCa. The
effect of the risk allele A at rs10486567 was stronger in the
presence of the risk allele A at rs4242382 (aOR=1.09, 1.01–1.18
vs. 1.01, 0.95–1.07), which indicates a synergistic epistasis
(Table 4). A similar finding was observed for the effect of
rs4242382 in relation to rs10486567 (aOR=1.18, 1.10–1.27, in
the absence of the latter vs. 1.09, 1.02–1.16, when carrying both).
Such an effect on risk modification between the two loci was also
observed for non-aggressive PrCa.
Figure 2 shows the probability of having at least four PrCa cases
among family members predicted by the Poisson regression model.
Table 3. The multiplicative model vs. the additive model of an association between the two SNPs and the risk of prostate cancer.
Prostate Cancer Non-aggressive Prostate Cancer Aggressive Prostate Cancer
SNPs Coefficient p-Value Coefficient p-Value Coefficient p-Value
Intercept 1.1815 1.0586 20.5446
rs4242382 (AA or GA vs GG) 0.0872 0.0992 0.0521
Intercept
rs10486567 (AA or GA vs GG) 0.0085 20.0088 0.0483
Interaction 0.0799 0.0002 0.0988 0.0497 0.0125 0.5445
doi:10.1371/journal.pone.0089508.t003
Table 4. Stratified odds ratios for rs10486567 and rs4242382 with respect to the risk of prostate cancer.
Stratum SNPs Odds ratio
Prostate Cancer
Stratified by rs4242382
AA or GA rs10486567 (AA or GA vs GG) 1.09(1.01–1.18)
GG rs10486567 (AA or GA vs GG) 1.01(0.95–1.07)
Stratified by rs10486567
AA or GA rs4242382(AA or GA vs GG) 1.18(1.10–1.27)
GG rs4242382(AA or GA vs GG) 1.09(1.02–1.16)
Non-aggressive Prostate Cancer
Stratified by rs4242382
AA or GA rs10486567 (AA or GA vs GG) 1.09(0.98–1.23)
GG rs10486567 (AA or GA vs GG) 0.99(0.90–1.08)
Stratified by rs10486567
AA or GA rs4242382(AA or GA vs GG) 1.22(1.09–1.37)
GG rs4242382(AA or GA vs GG) 1.10(1.01–1.21)
doi:10.1371/journal.pone.0089508.t004
Interactions and Epistasis in Prostate Cancer Risk
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Those who had the risk allele A at both rs4242382 and
rs10486567 showed higher probability of having at least four
affected relatives. Figure 3 also shows the probabilities of having at
least four PrCa cases among family members in combination with
having the risk allele A at rs4242382 and at rs10486567. Those
carrying the risk allele for both loci had a 13% higher risk for
having at least four PrCa cases among family members than those
not carrying the risk allele.
Discussion
In spite of numerous studies addressing genetic susceptibility to
prostate cancer, very few studies have been conducted to evaluate
the effects interactions (epistasis) on the disease penetrance by
using the state-of-the-art statistical analysis of joint effects.
Furthermore, our end-point was multiple PrCa cases within a
family, which has rarely been studied. Epistasis in genotype level is
defined as the interaction among multiple genes or loci, and this
joint genetic effect may be the factor behind ‘‘missing heritability’’,
a phenomenon linked to the unexplained portion of hereditary
cancer susceptibility, which is observed in PrCa. In the current
study, we used family-based data to investigate the effect of two
loci, rs4242382 at 8q24 and rs10486567 at 7p15.2, on multiple
PrCa cases within families with the Poisson regression method to
compare additive and multiplicative models. We demonstrated a
statistically significant association between the two individual loci
and multiple PrCa, as well as a synergistic gene-gene interaction
between the two risk alleles. Gene-gene interactions were
statistically significant under both models, but the multiplicative
model provided a better fit than the additive model with respect to
the likelihood ratio test with the AIC criterion. The genetic
interactions (joint effect of rs4242382 at 8q24 and rs10486567 at
7p15.2) resulted in a positive statistical epistasis (enhancement) in
the multiplicative model but a slightly negative epistasis (antago-
nistic effect) in the additive model. This statistical epistasis was also
observed for non-aggressive PrCa, but not for the aggressive PrCa.
Our findings for rs4242382 at 8q24 and rs 10486567 at 7p15.2
were consistent with the genome-wide study in which the risk
allele A of rs4242382 at 8q24 led to a 41% increase in the risk of
non-aggressive PrCa and a 66% risk increase in the aggressive
PrCa compared with the control group; the risk allele G of
rs10486567 at 7p15.2 was associated with a 18% decrease in non-
aggressive PrCa and 8% decrease in the aggressive PrCa [13]. The
association between rs4242382 at 8q24 and the risk for prostate
cancer has been consistently reported in a number of genome-wide
studies [2,8,20–24]. The risk allele G of rs10486567 is reported as
the major allele in the Europeans. In our study, the frequency of
the risk allele G was approximately 75%. However, the direction
of the association between rs10486567 at 7p15.2 and the risk of
prostate cancer has not been consistent in multiple studies. The
results published by Thomas et al. [13] as well as our study,
indicate an inverse association; in contrast, several others have
shown a positive association [15], [24]. The SNP rs10486567
located within intron 2 of JAZF1 gene on chromosome 7p15.2
encodes a three C2-H2-type zinc finger protein, which is a
transcriptional repressor of NR2C2, a nuclear orphan receptor
that is highly expressed in prostate tissue and interacts with the
androgen receptor. There is no biological interpretation for the
functional implications of JAZ1 in prostate carcinogenesis. It has
been reported that JAZF1 is a component of gene fusion with
SUZ12, which is found in endometrial stromal tumor. The inverse
association found in both Thomas’s and our study may be due to
the increased risk for T2D, which has been reported to be
inversely associated with PrCa [13]. The area on 8q24 is
associated to many cancers, for example breast, colon and bladder
cancer, in addition to PrCa, and the area is shown to have multiple
regulatory variants. Therefore, it is possible that the SNPs
analyzed here or other SNPs in linkage disequilibrium near the
tested ones affect the expression of the gene they resided in,
possibly acting as regulators for the other gene. Also, JAZF1 is
known to have alternatively spliced variants, which encode for
different protein isoforms but not all variants have been fully
characterized. These may be tissue type and/or SNP specific.
However, no explicit conclusions about the interactions between
these variants can be made without further functional validation.
The results presented here were from a relatively small sample set
and therefore additional studies are warranted, also in other
populations.
A family-based study design is ideal for assessing the indepen-
dent genetic influence of several SNPs and their joint effects with
other genetic determinants on the disease penetrance among
multiple PrCa cases. It can also provide an insight into the
functional and evolutionary consequences of epistasis.
We tested gene interactions between the two loci, rs4242382 at
8q24 and rs 10486567 at 7p, under the Fisher’s model of statistical
epistasis, and we found that the multiplicative model fitted the
findings better than the additive model. This suggests the presence
of linkage disequilibrium for these two loci [17]. However, a
negative epistasis was found in the context of an additive model,
whereas the multiplicative model suggested a positive epistasis.
Different measurements for epistasis could lead to different
interpretations; the model-dependence of joint effects has been
well established in epidemiology and biostatistics [17]. In
agreement with a previous study on the extension of common
epistasis model with different classes of statistical models [17], we
also found that adding different loci would yield different results.
For example, in our additive model, an inclusion of rs10486567
did not change the effect of rs4242382, whereas adding rs4242382
substantially affected the influence of rs10486567. A similar
Figure 2. A. The risk of having multiplex prostate cancer families with the SNP rs4242382. B. The risk of having multiplex of prostate cancer cases in a
family for the SNP of rs10486567
doi:10.1371/journal.pone.0089508.g002
Figure 3. Risk of having four or more prostate cancer cases
among family members with the SNPs rs4242382 and
rs10486567.
doi:10.1371/journal.pone.0089508.g003
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phenomenon was observed in the multiplicative model. However,
this epistasis was only observed in non-aggressive PrCa, but not in
the aggressive PrCa, which suggests that the evaluation of the two
loci cannot be used for identification of families with a risk of
developing aggressive PrCa in the Finnish population. This may
reflect the fact that both SNPs were originally found to be
associated with PrCa risk only, not disease outcome, and that the
later associations with disease outcome actually reflect other, yet
unknown, and possibly population-specific interactions.
In conclusion, we proposed a family-based study design to
demonstrate the effect of the previously reported SNP at 8q24,
known as rs4242382, on the risk of multiple PrCa. Our findings
suggest an interaction between rs4242382 and rs10486567 in both
multiplicative and additive models. The proposed method is useful
for identification of relevant variants in strong LD with the SNP of
interest as well as quantifying epistasis between two loci affecting
the penetrance of complex diseases and their traits.
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